Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O75923
UPID:
DYSF_HUMAN
Alternative names:
Dystrophy-associated fer-1-like protein; Fer-1-like protein 1
Alternative UPACC:
O75923; A0FK00; B1PZ70; B1PZ71; B1PZ72; B1PZ73; B1PZ74; B1PZ75; B1PZ76; B1PZ77; B1PZ78; B1PZ79; B1PZ80; B1PZ81; B3KQB9; O75696; Q09EX5; Q0H395; Q53QY3; Q53TD2; Q8TEL8; Q9UEN7
Background:
Dysferlin, encoded by the gene with accession number O75923, plays a pivotal role as a key calcium ion sensor facilitating the Ca(2+)-triggered synaptic vesicle-plasma membrane fusion. It is instrumental in the sarcolemma repair mechanism in skeletal muscle and cardiomyocytes, enabling rapid membrane resealing after mechanical stress. Dysferlin's alternative names include Dystrophy-associated fer-1-like protein and Fer-1-like protein 1.
Therapeutic significance:
Dysferlin's involvement in muscular dystrophies such as Limb-girdle muscular dystrophy, autosomal recessive 2, Miyoshi muscular dystrophy 1, and Distal myopathy with anterior tibial onset underscores its therapeutic significance. Understanding Dysferlin's function could lead to innovative therapeutic strategies targeting these debilitating conditions.